Warfarin Initiation with Interacting Antimicrobial
A 68-year-old woman (58 kg) with atrial fibrillation and a CHA2DS2-VASc of 4 is stable on warfarin 5 mg daily with INR 2.4–2.8 for the past year. She is admitted with a complicated urinary tract infection and started on oral trimethoprim-sulfamethoxazole (TMP-SMX) DS twice daily for 10 days. On day 4 of antibiotics, her INR is 5.8. She has no bleeding, no melena, and hemoglobin is unchanged at 12.1 g/dL. The hospitalist wants to give vitamin K 10 mg IV and hold warfarin. The patient asks whether she can just 'take a little less warfarin' and keep the antibiotic. She also takes omeprazole and metoprolol, unchanged for years.
1. Explain the mechanism(s) by which TMP-SMX raises INR in this patient and assess whether the interaction is dose- or time-dependent.
Read the worked answer
Two mechanisms converge:
- Protein-binding displacement: sulfamethoxazole is highly protein-bound and displaces warfarin from albumin, transiently raising free warfarin - this is early and largely transient.
- CYP2C9 inhibition: TMP-SMX inhibits CYP2C9 (the principal enzyme clearing S-warfarin, the more potent enantiomer), reducing clearance and raising INR. This is the dominant, sustained mechanism and is time-dependent - INR rises over several days as warfarin accumulates, which matches the day-4 rise. There is also a possible reduction in gut flora vitamin K production, but this is minor in someone with adequate dietary intake. The interaction is clinically significant at standard doses; INR elevation typically peaks around days 3–7. The key exam point: the rise is not a single transient displacement effect - CYP2C9 inhibition produces a sustained increase requiring dose reduction or antibiotic change, not just reassurance.
2. Critique the proposed management (vitamin K 10 mg IV + hold warfarin) and propose an alternative. What is the risk of the high-dose IV vitamin K in this setting?
Read the worked answer
Critique: INR 5.8 without bleeding does not warrant 10 mg IV vitamin K. Guidelines reserve IV vitamin K for serious/life-threatening bleeding or very high INR with bleeding risk; for asymptomatic INR 5–9, options are hold warfarin ± low-dose oral vitamin K (1–2.5 mg) only if bleeding risk is high. 10 mg IV is excessive and risks overcorrection and prolonged warfarin resistance - after large vitamin K doses, the patient may be subtherapeutic for days and require bridging, and IV vitamin K carries anaphylactoid risk. Alternative:
- Hold warfarin 1–2 doses and recheck INR in 24–48 h.
- Stop or switch TMP-SMX to a non-interacting antibiotic (e.g., nitrofurantoin if susceptible and renal function adequate, or another agent) - removing the CYP2C9 inhibitor is the cleanest fix.
- If TMP-SMX must continue, reduce warfarin dose empirically (often 25–50%) with frequent INR checks and consider oral vitamin K 1–2.5 mg only if INR continues rising or bleeding risk is high.
- No routine bridging needed if warfarin is only briefly held. Recheck INR daily until stable.